# Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

> **NCT05403385** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **iTeos Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- Metastatic NSCLC - Non-Small Cell Lung Cancer
- Locally Advanced NSCLC - Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** inupadenant
- **DRUG:** Placebo
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT05403385
- **Lead sponsor:** iTeos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-26
- **Primary completion:** 2025-06-13
- **Final completion:** 2025-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05403385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05403385, "Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05403385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*